☆ 4.4 Article

Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Article Oncology

An integrative pan-cancer analysis of COPB1 based on data mining

Heyan Chen et al.

Summary: COPB1 is upregulated in tumor tissues and high expression is beneficial to the survival of ESCA patients. In STAD, COPB1 expression is positively correlated with tumor infiltrating lymphocytes and immune checkpoint markers like PD-L1 and CTLA4. COPB1 may serve as a prognostic biomarker for pan-carcinoma and suggest an immune anti-tumor strategy for STAD.

CANCER BIOMARKERS (2021)

Add to Collection

Review Oncology

A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy

Peter G. Alexander et al.

Summary: CD274 is not a useful prognostic marker in CRC, but may be indicative of response to anti-PD-1 therapy. Standardization of assessment methodology is needed, with potential adoption of the CPS scoring system used in upper GI cancer. Thresholds for CRC are yet to be determined.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Rheumatology

Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival

Leslie Adda et al.

Summary: The occurrence of rheumatic adverse events in patients treated with immune checkpoint inhibitors is associated with better survival and tumor response, emphasizing the importance of early detection and management.

JOINT BONE SPINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Identification of a metabolic-related gene signature predicting the overall survival for patients with stomach adenocarcinoma

Yuan Nie et al.

Summary: A novel metabolic-related signature was identified for predicting prognosis in stomach adenocarcinoma patients. Patients in the high-risk group had significantly poorer survival outcomes compared to those in the low-risk group, with the predictive model showing good value. Additionally, gene set enrichment analyses revealed enriched pathways that may help explain the underlying mechanisms.

PEERJ (2021)

Add to Collection

Article Oncology

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

Beatriz Grandal et al.

Summary: The study evaluated PD-L1 expression in TNBC patients after NAC and found that PD-L1 positivity in tumor cells was significantly associated with more aggressive post-NAC tumor characteristics. The results suggest that a small subset of TNBC patients with extensive PD-L1 expression post-NAC may benefit from ICI treatment.

CANCERS (2021)

Add to Collection

Article Oncology

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Agnese Paderi et al.

Summary: It has been found that the presence of immune-related adverse events (irAEs) is associated with better clinical response to immunotherapy. Specifically, thyroid dysfunction and skin reactions are correlated with the efficacy of immune-checkpoint inhibitors in metastatic renal cell cancer patients. Additionally, experiencing multiple irAEs in a single patient is linked to improved tumor response.

CANCERS (2021)

Add to Collection

Article Oncology

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

Yu Rebecca Miao et al.

Summary: The study demonstrates that high expression of PD-L2 can impact the response to immune checkpoint blockade therapy, and constructing a high-affinity sPD-1 receptor can more effectively inhibit immune evasion mediated by PD-L1 and PD-L2, thus reducing tumor growth in ovarian cancer.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness

Shingo Inaguma et al.

JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Oncology

Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment

Qingquan Zeng et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity

Sang-Eun Lee et al.

CANCER RESEARCH AND TREATMENT (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Prognostic value of immune checkpoint molecules in breast cancer

Jun Fang et al.

BIOSCIENCE REPORTS (2020)

Add to Collection

Article Mathematical & Computational Biology

Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer

Yue Fan et al.

COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2020)

Add to Collection

Article Immunology

JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma

Feiguo Liang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Mining therapeutic and prognostic significance of STATs in renal cell carcinoma with bioinformatics analysis

Liangcheng Zhou et al.

GENOMICS (2020)

Add to Collection

Article Oncology

Calreticulin couples with immune checkpoints in pancreatic cancer

Xing Huang et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2020)

Add to Collection

Review Cell Biology

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

Fatemeh K. Dermani et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Add to Collection

Review Oncology

Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy

Zhongping Yin et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

CD4/CD8+T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis

Fangxuan Li et al.

CANCER MEDICINE (2019)

Add to Collection

Article Immunology

MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway (Publication with Expression of Concern. See vol. 43, pg. 505, 2021)

Chunhong Xiao et al.

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2018)

Add to Collection

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Add to Collection

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

Add to Collection

Review Immunology

Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

Abhishek D. Garg et al.

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection

Article Oncology

Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma

Yuan Li et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Advanced gastric cancer: Current treatment landscape and future perspectives

Antonia Digklia et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Article Oncology

Upregulated INHBA expression is associated with poor survival in gastric cancer

Quan Wang et al.

MEDICAL ONCOLOGY (2012)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Oncology

Genome-wide expression profile of sporadic gastric cancers with microsatellite instability

Mariarosaria D'Errico et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.